Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
19.74
USD
|
+4.28%
|
|
-4.91%
|
-15.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
633.9
|
895.8
|
737.9
|
2,563
|
1,301
|
1,365
|
-
|
-
|
Enterprise Value (EV)
1 |
633.9
|
627.4
|
549.6
|
2,221
|
775.8
|
977.5
|
1,083
|
1,023
|
P/E ratio
|
-7.65
x
|
-10.2
x
|
-7.32
x
|
-19.1
x
|
-8.08
x
|
-5.01
x
|
-4.4
x
|
-4.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
93.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
70.3
x
|
EV / EBITDA
|
-13.9
x
|
-8.47
x
|
-5.45
x
|
-19.3
x
|
-4.49
x
|
-3.93
x
|
-3.85
x
|
-3.47
x
|
EV / FCF
|
-17.8
x
|
-8.84
x
|
-6.9
x
|
-24
x
|
-5.34
x
|
-6.39
x
|
-5.18
x
|
-4.78
x
|
FCF Yield
|
-5.62%
|
-11.3%
|
-14.5%
|
-4.17%
|
-18.7%
|
-15.7%
|
-19.3%
|
-20.9%
|
Price to Book
|
2.6
x
|
3.46
x
|
4.36
x
|
6.54
x
|
2.29
x
|
3.12
x
|
4.98
x
|
4.85
x
|
Nbr of stocks (in thousands)
|
28,559
|
34,722
|
34,888
|
46,763
|
55,710
|
69,151
|
-
|
-
|
Reference price
2 |
22.20
|
25.80
|
21.15
|
54.80
|
23.35
|
19.74
|
19.74
|
19.74
|
Announcement Date
|
3/16/20
|
3/16/21
|
2/25/22
|
3/17/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
14.56
|
EBITDA
1 |
-45.65
|
-74.12
|
-100.8
|
-115.1
|
-172.8
|
-248.7
|
-281.1
|
-295
|
EBIT
1 |
-45.65
|
-80.15
|
-100.9
|
-115.2
|
-172.9
|
-239.8
|
-275.2
|
-278.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,911.11%
|
Earnings before Tax (EBT)
1 |
-43.76
|
-79.21
|
-100.8
|
-112
|
-151.8
|
-229.9
|
-266.5
|
-257.4
|
Net income
1 |
-43.76
|
-79.21
|
-100.8
|
-112
|
-151.8
|
-232.9
|
-274
|
-283.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,947.27%
|
EPS
2 |
-2.900
|
-2.520
|
-2.890
|
-2.870
|
-2.890
|
-3.940
|
-4.490
|
-4.163
|
Free Cash Flow
1 |
-35.63
|
-70.95
|
-79.68
|
-92.52
|
-145.4
|
-153
|
-209
|
-214.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,471.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/16/21
|
2/25/22
|
3/17/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-21.73
|
-32.43
|
-26.04
|
-27.58
|
-36.08
|
-25.41
|
-28.74
|
-35.62
|
-46.61
|
-61.87
|
-66
|
-71
|
-76
|
-81
|
-
|
EBIT
1 |
-24.35
|
-32.44
|
-26.05
|
-27.59
|
-36.09
|
-25.42
|
-28.75
|
-35.63
|
-46.62
|
-61.87
|
-57.87
|
-59.42
|
-61.93
|
-68.06
|
-67.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-24.33
|
-32.42
|
-26.03
|
-27.4
|
-35.54
|
-23.06
|
-25.83
|
-31.08
|
-39.66
|
-55.19
|
-54.55
|
-54.62
|
-57.35
|
-66.12
|
-
|
Net income
1 |
-24.33
|
-32.42
|
-26.03
|
-27.4
|
-35.54
|
-23.06
|
-25.83
|
-31.08
|
-39.66
|
-55.19
|
-54.56
|
-56.17
|
-58.75
|
-64.95
|
-68.85
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7000
|
-0.9300
|
-0.7400
|
-0.7700
|
-0.9200
|
-0.4900
|
-0.5500
|
-0.6000
|
-0.7100
|
-0.9900
|
-0.9525
|
-0.9717
|
-1.012
|
-1.120
|
-1.207
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
2/25/22
|
5/6/22
|
8/5/22
|
11/4/22
|
3/17/23
|
5/15/23
|
8/11/23
|
11/13/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
268
|
188
|
342
|
525
|
388
|
282
|
342
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-35.6
|
-71
|
-79.7
|
-92.5
|
-145
|
-153
|
-209
|
-214
|
ROE (net income / shareholders' equity)
|
-111%
|
-40.9%
|
-47.1%
|
-45.2%
|
-35.2%
|
-51.3%
|
-94.1%
|
-115%
|
ROA (Net income/ Total Assets)
|
-40.7%
|
-38.5%
|
-43%
|
-40.6%
|
-32.4%
|
-51.7%
|
-65.8%
|
-77.7%
|
Assets
1 |
107.6
|
205.7
|
234.4
|
276.1
|
468.4
|
450.4
|
416.5
|
364.9
|
Book Value Per Share
2 |
8.540
|
7.450
|
4.860
|
8.380
|
10.20
|
6.320
|
3.960
|
4.070
|
Cash Flow per Share
2 |
-
|
-
|
-2.290
|
-
|
-
|
-2.480
|
-3.250
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
3.86
|
5.71
|
7.14
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
49.05%
|
Announcement Date
|
3/16/20
|
3/16/21
|
2/25/22
|
3/17/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
19.74
USD Average target price
47.5
USD Spread / Average Target +140.63% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.46% | 1.37B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|